Article

invezz.com on 2021-08-04 22:26

As Simon Property edges lower despite the BofA upgrade, should you buy or sell?

Zymergen expects no product revenue this year and immaterial product revenue in 2022. The biofacturing company's CEO Josh Hoffman stepped down.

Related news